RUNX2-AS1

Across TCGA pan-cancer cohorts, RUNX2-AS1 RNA differs between tumor and matched normal tissue in 8 of 18 cancer types tested, making tumor–normal expression one of RUNX2-AS1’s most consistent transcriptional readouts.

The strongest signal is observed in breast invasive carcinoma (BRCA), where RUNX2-AS1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RUNX2-AS1 is over-expressed in tumor, although a few such as KIRC and KICH show the opposite, repressed pattern.

BRCA, KIRC, and STAD are the cancer types where RUNX2-AS1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RUNX2-AS1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BRCA	All	All	+0.072	.011	6	view →
KIRC	All	IV	−0.041	.008	4	view →
STAD	All	All	+0.036	.002	4	view →
HNSC	Male	All	+0.034	.002	4	view →
KICH	All	All	−0.032	.005	3	view →
THCA	Female	All	−0.056	<.001	2	view →
ESCA	Female	All	+0.093	.046	1	view →
KIRP	Male	All	−0.024	.032	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 8 strongest of 8 lineages.

RUNX2-AS1–BRCA

Open the BRCA breakdown →